NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK

Name: NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK (English version)
SKU: IN-S483

Angelmar, Reinhard;Bieser, Andrea

Product #:IN-S483

Supplier:INSEAD

Discipline:Marketing

Setting:Europe

Details:Case (PDF) • 31 pages • 2006-07-01

Subjects:

Marketing

Geography:

Europe

Your Price:

$9.71

Purchase this material with a free Educator Account and enjoy more benefits:

Free Educator Copy
Free Teaching Notes
Build your coursepack
Discounted academic price

NICE (National Institute for Health and Clinical Excellence) reviews the cost effectiveness of medicines for the treatment of multiple sclerosis (annual cost per patient 10,000-18,000) and does not authorize their use within the UK National Health Service. However, an agreement between the manufacturers and the Department of Health is reached on an innovative risk sharing scheme.